The stock of Sientra (NAS:SIEN, 30-year Financials) is believed to be significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $7.09 per share and the market cap of $406.1 million, Sientra stock is estimated to be significantly overvalued. GF Value for Sientra is shown in the chart below.
Because Sientra is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth, which is estimated to grow 10.25% annually over the next three to five years.
Link: These companies may deliever higher future returns at reduced risk.
It is always important to check the financial strength of a company before buying its stock. Investing in companies with poor financial strength have a higher risk of permanent loss. Looking at the cash-to-debt ratio and interest coverage is a great way to understand the financial strength of a company. Sientra has a cash-to-debt ratio of 0.82, which is worse than 69% of the companies in the industry of Medical Devices & Instruments. The overall financial strength of Sientra is 2 out of 10, which indicates that the financial strength of Sientra is poor. This is the debt and cash of Sientra over the past years:
Companies that have been consistently profitable over the long term offer less risk for investors who may want to purchase shares. Higher profit margins usually dictate a better investment compared to a company with lower profit margins. Sientra has been profitable 0 over the past 10 years. Over the past twelve months, the company had a revenue of $71.2 million and loss of $1.79 a share. Its operating margin is -87.19%, which ranks worse than 76% of the companies in the industry of Medical Devices & Instruments. Overall, the profitability of Sientra is ranked 1 out of 10, which indicates poor profitability. This is the revenue and net income of Sientra over the past years:
One of the most important factors in the valuation of a company is growth. Long-term stock performance is closely correlated with growth according to GuruFocus research. Companies that grow faster create more value for shareholders, especially if that growth is profitable. The average annual revenue growth of Sientra is -9.4%, which ranks worse than 77% of the companies in the industry of Medical Devices & Instruments. The 3-year average EBITDA growth is 21.3%, which ranks better than 67% of the companies in the industry of Medical Devices & Instruments.
Another method of determining the profitability of a company is to compare its return on invested capital to the weighted average cost of capital. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. When the ROIC is higher than the WACC, it implies the company is creating value for shareholders. For the past 12 months, Sientra's return on invested capital is -68.20, and its cost of capital is 15.68. The historical ROIC vs WACC comparison of Sientra is shown below:
In conclusion, the stock of Sientra (NAS:SIEN, 30-year Financials) is estimated to be significantly overvalued. The company's financial condition is poor and its profitability is poor. Its growth ranks better than 67% of the companies in the industry of Medical Devices & Instruments. To learn more about Sientra stock, you can check out its 30-year Financials here.
To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.
